Ovid Therapeutics price target raised to $2 from $1.50 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Ovid Therapeutics (OVID) to $2 from $1.50 and keeps a Buy rating on the shares. OV329’s initial clinical data show robust safety and position the compound favorably for proof-of-concept clinical development, the analyst tells investors in a research note.